A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer: From a Multicenter Phase II Cohort to a Phase III Randomized Controlled Study

Conditions: Locally Advanced Rectal Carcinoma Interventions: Drug: Tislelizumab Sponsors: Beijing Friendship Hospital; Beijing Chao Yang Hospital; Peking University Cancer Hospital& Institute; CHINA-JAPEN FRIENDSHIP HOSPITAL; Peking Union Medical College Hospital; Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Fudan University; Changhai Hospital; RenJi Hospital; Sir Run Run Shaw Hospital, affiliated with the Zhejiang University School of Medicine; Shandong Provincial Hospital; Zhongnan Hospital of Wuhan University& Second Clinical Hospital of Wuhan University; The First Affiliated Hospital of Zhengzhou University; West China School of Medicine and West China Hospital, Sichuan University; Sichuan Academy of Medical Sciences; The Sixth Affiliated Hospital, Sun Yat-sen University; The First Hospital of Jilin University; First Hospital of China Medical University; Army Medical Center of PLA; The First Affiliated Hospital of Anhui Medical University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials